Tracer library / [177Lu]Lu-rhPSMA-10

[177Lu]Lu-rhPSMA-10

Also written as [177Lu]Lu-rhPSMA-10; [Lu-177]Lu-rhPSMA-10

Radionuclide: Lu-177 t½ 9585 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Prostate cancer Dosimetry and biodistribution studies PSMA-directed radioligand therapy

What it is

Compound class: radiohybrid PSMA-targeted ligand
Target / mechanism: prostate-specific membrane antigen (PSMA) PMID 35086894
Clinical application: metastatic castration-resistant prostate cancer PMID 40325261
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [177Lu]Lu-rhPSMA-10, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityOsmolalityMolar activityMetal impuritiesLu-177m

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Lu-177 preparation -> Lu-177m content (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [177Lu]Lu-rhPSMA-10.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with Lu-177. | Stage 30 (2026-09-18): Stage was 'phase I'; normalised to 'Clinical research', original wording kept here.